A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2015
At a glance
- Drugs LTX 315; Tertomotide
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Lytix Biopharma
- 14 Feb 2012 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 07 Jun 2011 Planned end date changed from 1 Aug 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 07 Dec 2010 First patient treated, according to a Lytix Biopharma media release.